QLT has positive outcomes treating LCA
April 20, 2010 by stephenkilmer · Leave a Comment
QLT (NASDAQ:QLTI; TSX:QLT) has released “positive outcomes” from interim results of the first three subjects enrolled in a Phase 1b clinical proof-of-concept study of its QLT091001 treatment for Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease. LCA leads to retinal dysfunction and significant visual impairment beginning at birth. Based on the positive results [...]
Listen to BioTuesdays 
